INSPHERE uses image sensors and Artificial Intelligence (AI) to guide and correct robot positioning during the manufacturing process, ensuring right-first-time production. The company argues that industrial robots are not completely accurate and can experience unplanned downtime that can cost up to £10,000 per minute. INSPHERE asserts that its solution allows factory operators to operate safely with less downtime, and with multiple robot and human operators. The company has developed three products since 2013 which have received recognition in the aerospace and industrial automation sectors. INSPHERE is now launching IONA, a network of sensors that can be permanently deployed in a manufacturing environment to monitor and control industrial robots. IONA, the company points out, uses both hardware and software to correct errors taking into account the robot and its relationship to the workpiece. INSPHERE will use the investment to diversify the reach of IONA across markets.
days to go:
Expired
investment:
£1,149,999
The world's first automated suturing tools for safe closure of standard and endoscopic wounds. Sutrue have already patented their devices and use industry-standard needles to offer clinical quality with improved speed and accuracy at the touch of a button. Needles are held in disposable cartridges as a safety feature to prevent injury when piercing skin with contaminated needles. This protects staff both during and after surgery for those working in medical and veterinary environments.
Sutrue is raising finance for the production process of their equipment, as well as applying for CE regulation via medical evaluations to receive approval to deploy their products in human and animal surgeries.
days to go:
Expired
investment:
Withheld
OPTIFarm is the world’s only real-time, remote, 24/7 optimisation service for livestock farms. The company argues that current livestock production facilities lack a systematic way of monitoring production, animal welfare or staff training needs on a continuous basis. It stresses that its model combines the knowledge of trained experts with raw data gathered from livestock consisting of metrics like feed consumption, feed availability, water, temperature, humidity, and air pressure. The company combines the aforementioned data with advanced software and data analytics offering livestock businesses 24/7 monitoring providing full status reports every 90 minutes. OPTIFarm asserts that this enables farms to optimise feed, water and climate to provide the best conditions for their livestock. OPTIFarm’s service is currently generating c. £25,000 per month in recurring revenues from poultry clients in 14 countries across the globe. The company stated it will use the investment received to prepare the business for rapid scale-up growth over the next five years.
days to go:
Expired
investment:
Withheld
HelloDone automates conversations across messaging apps such as WhatsApp, Facebook Messenger, and Instagram for the transportation, home delivery and utility sectors. HelloDone stresses that its Software as a Service (SaaS) enables more than 80% of inbound queries to be resolved automatically between customers of retailers and global carriers. HelloDone states that its portal drastically reduces the customer service burden and creates new dialogues with the customer for enhanced revenues. The company claims that it launched its portal in October 2020 and onboarded its first client in four months, followed by signing large online retailers such as Charles Tyrwhitt and Footasylum. It has also signed contracts with leading UK fast fashion groups and major US retailers. HelloDone is tracking £330,000 worth of Annual Recurring Revenue (ARR) for 2021 and forecasting revenues of £65 million by 2025. They state they will use the investment to arrange flagship brands signed, build on evidence/success metrics and build scale and pace ready for a planned Series-A in mid-2022.
days to go:
Expired
investment:
£700,003
Care Line Live is an award-winning revolutionary monitoring and management platform for Home Care Agencies. CLL is a client-based system that enables home care agencies to run their businesses from any place. It reduces administration, automates processes, easily rosters client visits and improves efficiency and productivity by giving the client more Time to Care. It increases client and carer satisfaction, provides accessible and responsive support, increases compliance for CQC purposes, generates higher profits through improved efficiency and capacity. The future product road map includes integration with 3rd party home automation platforms that will allow home care agencies to offer further services to their clients, such as secure key-less entry.
days to go:
Expired
investment:
£367,000
Third Bladetec Bitcoin Mine is aiming to be the largest bitcoin mine in the UK. They are looking to raise £10million to fund the building and operations of the mine.
days to go:
Expired
investment:
£1,195,000
The Face Recognition Company (FRC) produces 90%+ accurate face recognition solution. In 2016, the company came up with the objective to develop the most accurate and cost-effective facial recognition solution. This technology is suitable for commercial applications or crime and other security uses. Additionally, the FRC's go-to-market strategy incorporates working through large integrators/partners/approved installers, eight of which are ready to promote and install its product to their own customer base. The FRC team has technically developed this solution by combining 100 years of experience in facial recognition. In June 2018, FRC had filed for two patents: first, ‘Recognition of 3D Objects’ and second, 'Method of and System for Recognising a Human Face’. Where suitable, FRC has also set-up an EIS tax relief.
days to go:
Expired
investment:
£215,600
MedicSpot is a healthcare company that is aiming to revolutionise healthcare delivery by combining the advantages of online and offline care. The company provides patients at designated hospitals with diagnostic tools like a stethoscope, oximeter, blood pressure monitor and thermometer which, in turn, is connected to the MedicSpot network. Onboard General Physicians (GPs) engage in live sessions with patients, guide them on how to use the tools, and perform a variety of diagnoses like listening to a patient’s heart and lungs, looking down their throat and into their ears, taking their blood pressure and oxygen readings, and measuring their body temperature. The company is also expanding into another subsidiary, Arc Health, which it claims will perform the aforementioned tasks with more efficiency and accuracy. The company will use the investment to increase the number of Medicspot clinics to 1,000, gain further NHS market share, launch a corporate business model and allow international pilots to take place.
days to go:
Expired
investment:
£1,048,396
Buyerdock is a Software as a Service (SAAS) global discovery platform that allows retail buyers instant access to compliant ready brands through the company's intelligent cloud technology. Buyerdock enables each supplier to upload details like product information, barcodes, images, and pack size on the portal. Retail buyers can then scrutinise all the available information within specific product categories and select the inventory they wish to purchase intuitively. Buyerdock received a mention from the former CEO of Sainsbury's that the former will speed up the buying process from 6 months to under 3 for retail buyers. The company is in talks with the top six UK retailers, such as Tesco, Marks & Spencer, Home Retail Group, Sainsbury's, Asda, and Morrisons. It will use the investment to grow its business and target the approximate 306,000 retail outlets in the UK, of which around 200,000 are independent retailers.
days to go:
Expired
investment:
£121,157
Zentraxa is focused on precision bioengineering to produce peptides with predictable properties tailored towards purpose. The company points out that peptides are amino acids that are the building blocks of certain proteins needed by the skin, like collagen and elastin. It has come out with a synthetic biology platform, Zentide, that designs, produces and tests novel peptides. Zentraxa argues that Zentide can circumvent previously existing bio-design limits imposed by conventional peptide synthesis and produce tailor-made biomaterials for healthcare, personal care and industrial uses. Zentraxa is initially targeting healthcare with its first biomaterial, a debondable adhesive, for use in wound care. The company asserts that the material has other uses such as cosmetics and industrial applications due to its ability to bond strongly while still being easily and painlessly removable. Zentraxa will use the investment to create a portfolio of other biomaterials for licensing to global businesses in the health and industrial sectors via its Zentide platform.
days to go:
Expired
investment:
£1,040,000
